tony

/Tony Chen

About Tony Chen

Tony Chen is Chairman and Co-Founder of FDAzilla, and served as Founding CEO from 2010 to 2017.

PRESS RELEASE – FDAzilla Announces New CEO

CHICAGO, IL – October 18, 2017 FDAzilla, the leading software platform for GMP intelligence and analytics, is delighted to announce the appointment of Michael de la Torre as its new CEO, effective October 19, 2017. FDAzilla is a vital tool for FDA-regulated industries such as Pharmaceuticals, Medical Devices, CMOs, and Food Manufacturers that need insights and benchmarks on FDA inspections [...]

By |2017-10-18T05:43:30-05:00October 18th, 2017|FDAzilla|

FDA Sent These 11 Warning Letters for Pharma Companies | August 2017

We took a snapshot of the 11 warning letters the FDA sent to pharmaceutical companies last month.  Drug manufacturing violations ranged from failing to keep drug product infestation free to failing to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the proper education, training, and experience. From pharmaceuticals in China, Georgia, [...]

By |2018-02-01T11:34:07-05:00September 20th, 2017|Biopharma / Pharma, FDA, FDA Warning Letters, quality assurance|

FDA Sent These 9 Warning Letters for Pharma Companies | July 2017

We took a snapshot of the 9 warning letters the FDA sent to pharmaceutical companies last month.  Drug manufacturing violations ranged from “adulterated and misbranded drug products” to sites “failing to sanitize and/or sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination.” From pharmaceuticals in Italy, Tennessee, and more, here they are (starting with the most recent): [...]

FDA Sent These 5 Warning Letters for Pharma Companies | June 2017

*August 3 update: we added 2 additional warning letters that were released by the FDA after we published this post on July 12, 2017.* We took a snapshot of the 5 warning letters the FDA sent to pharmaceutical companies last month.  Drug manufacturing violations ranged from “misbranded products” to sites “failing to investigate the unexplained discrepancy.” From pharmaceuticals in China, [...]

By |2017-11-06T03:19:25-05:00July 12th, 2017|FDA, FDA Inspections, FDA Warning Letters, FDAzilla, quality assurance|